Application of Polymers as Drug Nanocarriers in the Oral Treatment of Ulcerative Colitis DOI
Xiaoqing Liu, Lianghui Huang,

Enguang Wu

et al.

ChemistrySelect, Journal Year: 2024, Volume and Issue: 9(41)

Published: Oct. 29, 2024

Abstract Ulcerative colitis (UC) is a chronic non‐specific inflammatory disease of the intestines with high prevalence. Polymer‐prepared nanoparticles are well‐targeted, highly biocompatible, and have potential for personalized therapy. Polymer able to achieve localized therapy through their unique design. First, this review compares advantages disadvantages natural synthetic polymeric materials as well describes application in UC Then, preparation, characterization methods, current challenges common polymer presented. Next, one‐by‐one examples nanoparticle‐targeted drug delivery strategies treatment In addition, nanoparticle‐based therapeutic approaches UC, including anti‐inflammatory therapies, reactive oxygen species scavenging intestinal flora modulation Finally, future research directions discussed identified. The aim paper provide valuable references guidance researchers design develop novel therapies.

Language: Английский

Nanoparticle innovations in targeted cancer therapy: advancements in antibody–drug conjugates DOI Creative Commons
Magdi T. Abdelhamid, Al-Hassan Soliman Wadan,

Hosam A. Saad

et al.

Naunyn-Schmiedeberg s Archives of Pharmacology, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 18, 2025

Language: Английский

Citations

4
Formulation, Optimization, and Evaluation of Lornoxicam-Loaded Novasomes for Targeted Ulcerative Colitis Therapy: In Vitro and In Vivo Investigations DOI
Asmaa Badawy Darwish, Abeer Salama, Inas Essam Ibrahim Al-Samadi

et al.

Journal of drug targeting, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 21

Published: Jan. 20, 2025

The purpose of this work was to create and assess Lornoxicam (LOR) loaded Novasomes (Novas) for the efficient treatment ulcerative colitis. study performed using a 23 factorial design investigate impact several formulation variables. Three separate parameters were investigated: Surface Active agent (SAA) type (X1), LOR concentration (X2), SAA: Oleic acid ratio (X3). dependent responses included encapsulation efficiency (Y1: EE %), particle size (Y2: PS), zeta potential (Y3: ZP), polydispersity index (Y4: PDI). vesicles demonstrated remarkable efficiency, ranging from 81.32 ± 3.24 98.64 0.99%. vesicle sizes ranged 329 9.88 583.4 9.04 nm with high negative values. release pattern Novas' biphasic adhered Higuchi's model. An in-vivo assessed how LOR-Novas affected rats' acetic acid-induced colitis (UC). optimized effectively reduced colonic ulceration (P < 0.05) inflammatory pathway via inhibiting Toll-like receptor 4 (TLR4), Nuclear factor kappa β (NF-κβ) inducible nitric oxide (iNO). At same time, it elevated Silent information regulator-1(SIRT-1) glutathione (GSH) colon contents. Thus, current suggested that LOR- Novas may be viable

Language: Английский

Citations

3
Novel Nose-to-brain delivery of carbenoxolone via mucoadhesive solid lipid nanoparticles for Parkinson’s symptoms management: In vitro and in vivo evaluation in a rotenone-induced rat model DOI
Hisham A. Nematalla, Mona Elharoun,

Somaia N Bargash

et al.

International Journal of Pharmaceutics, Journal Year: 2025, Volume and Issue: 670, P. 125197 - 125197

Published: Jan. 8, 2025

Language: Английский

Citations

2
Lipid core-chitosan shell hybrid nanoparticles for enhanced oral bioavailability of sorafenib DOI

Najam-us Sahar,

Maleeha Gul,

Ho-Ik Choi

et al.

International Journal of Biological Macromolecules, Journal Year: 2025, Volume and Issue: 299, P. 140030 - 140030

Published: Jan. 21, 2025

Language: Английский

Citations

1
Nanomedicine for colon-targeted drug delivery: strategies focusing on inflammatory bowel disease and colon cancer DOI
Ankaj Kumar,

Klaudi K. Vaiphei,

Naveen Singh

et al.

Nanomedicine, Journal Year: 2024, Volume and Issue: 19(15), P. 1347 - 1368

Published: June 10, 2024

The nanostructured drug-delivery systems for colon-targeted drug delivery are a promising field of research localized diseases particularly influencing the colonic region, in other words, ulcerative colitis, Crohn's disease, and colorectal cancer. There various approaches designed effective disease treatment, including stimulus-based formulations (enzyme-triggered systems, pH-sensitive systems) magnetically driven systems. In addition, targeted by means overexpressed receptors also offers site specificity reduces resistance. It covers GI tract-triggered emulsifying nontoxic plant-derived nanoformulations as advanced techniques well nanotechnology-based clinical trials toward diseases. This review gives insight into advancements to meet or requirements.

Language: Английский

Citations

5
Oral Lipid Nanoparticles for Improving the Efficiency of Drug Delivery Systems in Ulcerative Colitis: Recent Advances and Future Prospects DOI Creative Commons
Shuangli Zhu, Zhenlin Yang, Yulong Liu

et al.

Pharmaceutics, Journal Year: 2025, Volume and Issue: 17(5), P. 547 - 547

Published: April 23, 2025

Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by persistent, recurrent, and relapsing inflammation of the mucosal layer. Its pathogenesis complex not yet fully understood, with current treatments mainly focused on alleviating symptoms through pharmacological methods. Direct drug administration for UC often leads to poor intestinal bioavailability, suboptimal targeting, an increased risk resistance. Therefore, there urgent need effective delivery systems. Lipid nanoparticles (LNPs) are promising candidates due their high biocompatibility, stability, customizable properties. Oral administration, as preferred treatment approach UC, offers benefits such convenience, cost-effectiveness, better patient compliance. However, oral systems must navigate gastrointestinal tract effectively target colonic lesions, posing significant challenges LNP-based Researchers exploring ways enhance efficiency adjusting LNP composition, surface functionalization, coating. This article reviews recent advancements in research aimed at improving discusses future prospects.

Language: Английский

Citations

0
Rivaroxaban loaded lipid carriers integrating EPA oil: A novel paradigm in drug repurposing for navigating colon targeted oral treatment for ulcerative colitis. DOI
Walaa A. El‐Dakroury, Abdelrahman R. Said,

Sherif S. Abdel Mageed

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2025, Volume and Issue: unknown, P. 106985 - 106985

Published: April 1, 2025

Language: Английский

Citations

0
Cell Membrane‐Coated Lipid Nanoparticles for Drug Delivery DOI Creative Commons
Moataz B. Zewail, Guangze Yang,

Yilong Fan

et al.

Aggregate, Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

ABSTRACT Cell membrane coating (CMC) of nanoparticles (NPs) has emerged as a prominent strategy that gained significant attention and achieved notable progress across various therapeutic sectors. Coating NPs with natural cell membranes endows them functions addresses challenges in drug delivery, such prolonging circulation time, reducing immunogenicity, improving targeting efficiency cellular communication. Among the different NPs, lipid (LNPs) have revolutionized field nanomedicine by providing advantageous features for delivery. The versatile characteristics LNPs synergize well membranes’ biomimetic properties, creating hybrid structures enhanced functionalities diverse biomedical applications. A more advanced form significantly capabilities can be through CMC. However, opportunities remain further advancements, ongoing efforts focused on discovering innovative applications fully harnessing potential this promising combination. This article provides critical review recent coated‐LNPs (CMC‐LNPs). First, LNP types, their preparation methods, strategies are summarized. development, functions, CMC‐LNPs then discussed. Last, advantages, limitations, challenges, future perspectives presented.

Language: Английский

Citations

0
Desosomes and desimicelles − a novel vesicular and micellar system for enhanced oral delivery of poorly soluble drug: Optimization of in vitro characteristics and in vivo performance DOI
Abdelrahman R. Said, Gihan F. Asaad, Marwa E. Shabana

et al.

European Journal of Pharmaceutics and Biopharmaceutics, Journal Year: 2024, Volume and Issue: 200, P. 114324 - 114324

Published: May 15, 2024

Language: Английский

Citations

3
Development of fexofenadine self-microemulsifying delivery systems: an efficient way to improve intestinal permeability DOI
Ziba Islambulchilar, Ashkan Barfar, Shahla Mirzaeei

et al.

Therapeutic Delivery, Journal Year: 2024, Volume and Issue: 15(8), P. 593 - 604

Published: June 28, 2024

Aim: The present study aimed to prepare and evaluate fexofenadine self-microemulsifying drug-delivery systems (SMEDDS) formulation determine compare its intestinal permeability using in situ single-pass perfusion (SPIP) technique. Methods: Fexofenadine-loaded SMEDDS were prepared optimized. Droplet size, polydispersity index, zeta potential, drug release evaluated. Results: Optimized consisted of 15% oil, 80% surfactant 5% cosolvent. size loading optimized was 13.77 nm 60 mg/g it has released 90% content. Intestinal threefold enhanced compared with free fexofenadine. Conclusion: results our revealed that could be a promising tool for oral delivery dissolution rate permeability.

Language: Английский

Citations

2